Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:PEAR Pear Therapeutics (PEAR) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Pear Therapeutics Stock (NASDAQ:PEAR) 30 days 90 days 365 days Advanced Chart Ad Genesis Gold GroupBuffett Dumps $982 Million in BofA Stock—What Does He Know?Buffett's been eerily quiet about his reasons, but his actions speak volumes. When someone with his track record starts pulling out of the market, it's time to pay attention.Get your FREE, no-obligation Wealth Protection Guide now Get Pear Therapeutics alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume66.30 million shsAverage Volume7.75 million shsMarket Capitalization$4.17 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewPear Therapeutics, Inc., a commercial-stage healthcare company, develops and sells software-based medicines. Its commercial products are reSET for the treatment of substance use disorder related to alcohol, cannabis, cocaine, and stimulants; reSET-O for the treatment of opioid use disorder in combination with buprenorphine; and Somryst, a software-based treatment for chronic insomnia. The company is also developing a pipeline of 14 product candidates focusing on psychiatry, neurology, and outside of central nervous system therapeutic areas, such as gastrointestinal, oncology, and cardiovascular. Pear Therapeutics, Inc. was incorporated in 2013 and is based in Boston, Massachusetts.Read More… Buffett Dumps $982 Million in BofA Stock—What Does He Know? (Ad)Buffett's been eerily quiet about his reasons, but his actions speak volumes. When someone with his track record starts pulling out of the market, it's time to pay attention.Get your FREE, no-obligation Wealth Protection Guide now Receive PEAR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pear Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address PEAR Stock News HeadlinesRachel Reeves tries cell sorting experiments at Quell TherapeuticsNovember 14, 2024 | msn.com49 US startups have become unicorns so far in 2024: Here’s the full listOctober 25, 2024 | techcrunch.comBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…November 24, 2024 | Crypto 101 Media (Ad)Vibes for digital health deals improve after slumpOctober 22, 2024 | msn.comPursueCare Introduces RESET® and RESET-O®—FDA-Authorized Digital Therapeutics for Addiction TreatmentOctober 16, 2024 | finance.yahoo.comAvalyn CEO Lyn Baranowski Named a PharmaVoice 100 HonoreeOctober 8, 2024 | finance.yahoo.comNew York tech investor and serial entrepreneur Kevin Ryan explains when to sell your companySeptember 29, 2024 | msn.comGeorge Church spinout gets $65M to ‘revolutionize’ cell therapySeptember 19, 2024 | bizjournals.comSee More Headlines PEAR Stock Analysis - Frequently Asked Questions What other stocks do shareholders of Pear Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Pear Therapeutics investors own include Meta Platforms (META), LyondellBasell Industries (LYB), AbCellera Biologics (ABCL), Atai Life Sciences (ATAI), CVS Health (CVS), uniQure (QURE) and Absci (ABSI). Company Calendar Today11/24/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Health services Sub-IndustryN/A Current SymbolNASDAQ:PEAR CUSIPN/A CIK1835567 Webpeartherapeutics.com Phone617-925-7848FaxN/AEmployees300Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.22) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-75,490,000.00 Net Margins-594.70% Pretax Margin-594.70% Return on Equity-217.85% Return on Assets-95.20% Debt Debt-to-Equity RatioN/A Current Ratio1.48 Quick Ratio1.48 Sales & Book Value Annual Sales$12.69 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$0.22 per share Price / BookN/AMiscellaneous Outstanding Shares142,739,000Free Float98,918,000Market Cap$4.17 million OptionableNot Optionable Beta0.45 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report This page (NASDAQ:PEAR) was last updated on 11/24/2024 by MarketBeat.com Staff From Our PartnersTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredThis company will win the AI race Rome wasn’t built in a day… But there is another lesser-known type of keystone, one that plays an equally c...Porter & Company | SponsoredPopular Stocks at Risk Under Trump—Are You Holding These?The Stocks Most At-Risk from Trump’s Victory Free e-book reveals sectors – and stocks within them – likely ...StockEarnings | SponsoredAre Your Retirement Savings Really Safe?What They Don’t Want You to Know About Your 401(k)The 2008-2010 crisis wiped out almost 50% of the value of retirement funds. If you knew it was coming, wouldn'...American Hartford Gold | SponsoredDonald Trump can’t save you from this crisisElon Musk: “This Is The Most Destructive Force In History” Elon Musk claims a terrifying new economic force...Wide Moat Research | Sponsored#1 Crypto of 2024Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pear Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pear Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PEAR Stock Alerts